Ginkgo Bioworks Reports Third-Quarter Results, Signs First Autonomous Lab Sale
Ginkgo Bioworks reported results for the quarter ended September 30, 2026, and signed its first autonomous lab sale to a top-tier pharmaceutical company.
Story updates
09:07:39 PM UTC
SquawkNews
Ginkgo announced Q3 2026 results and its first autonomous lab sale, to pharma company Novo. The release provides no financial figures or prior-period comparisons.Material DetailsContext by AI AnalystThe sale is an early commercial milestone for Ginkgo's autonomous lab offering, while the release pr…
09:16:23 PM UTC
SquawkNews
Ginkgo Bioworks reported third-quarter 2026 revenue of $27.7 million, down 6% from a year earlier, while its net loss from continuing operations narrowed to $41.0 million. Adjusted EBITDA loss improved to $22 million from $53 million in the prior-year quarter. The company also announced its first a…
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, “Ginkgo”) today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information, will be availa…